GSK price forecast: Sideways move expected as shares hold above major averages

Traders Union
All News
Financial News
GSK slips 0.24% to GBX 1,783.78

Highlights

GSK repurchased 180,000 ordinary shares at an average price of 1,766.33 pence, continuing its share buyback program and holding these as treasury shares.
Since launching its buyback program on September 30, 2025, GSK has cumulatively acquired 10,138,000 shares, signaling sustained capital return to shareholders.
The ongoing buyback activity is underpinned by strong financial results and recent vaccine breakthroughs, reinforcing confidence in GSK's operational momentum.

Share buybacks and vaccine gains drive positive investor sentiment

GSK extended its share buyback initiative by acquiring 180,000 ordinary shares at an average price of 1,766.33 pence, to be held as treasury shares. This follows the ongoing program with a cumulative total of 10,138,000 shares repurchased since its launch on September 30, 2025. The company’s consistent buyback activity and solid financial results have been supported by recent vaccine breakthroughs.

Bullish momentum confirmed as oscillators highlight limited divergence

Short-, medium-, and long-term bullish trends remain intact with GSK above the MA-20, MA-50, and MA-200. Near-term technical support sits at the Ichimoku Kijun level (GBX 1,713.25), while the MA-50 acts as dynamic resistance. Momentum signals are positive with MACD and ADX indicating upward bias; RSI and CCI are in buy or neutral range, the Stochastic RSI reads oversold, but BBP signals buyers are currently dominant. The Awesome Oscillator is neutral, and the price action is contained mid-range between GBX 1,793.50 and GBX 1,774.50 after a modest 0.24% intraday pullback, with oscillators showing minor divergence.

Upward bias expected as volatility narrows near technical boundaries

For the coming week, GSK is projected to trade within GBX 1,765.00 to GBX 1,890.00, reflecting moderate volatility. Sideways movement is the base case scenario, but there is a strong probability (above 80%) for an upward move, making a downward break less likely. A breakout above GBX 1,890.00 could occur if buying momentum persists, while intensified selling pressure could see prices fall below GBX 1,765.00.

Viktoras Karapetjanc, expert at Traders Union, sees GSK’s ongoing buyback activity as a show of management conviction. He notes that the company’s above-average momentum and positive fundamentals are supported by recent vaccine breakthroughs. Karapetjanc believes price action reflects strong market sentiment and robust institutional confidence. "As long as GSK maintains its position above key support levels, I expect continued resilience and attractive upside potential for investors."

Previously it was noted that GSK continued its share buyback activity and established a new partnership to advance tuberculosis treatment. The technical outlook described overbought momentum alongside robust trend based on market indicators.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.